Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,736 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer.
Bakht MK, Yamada Y, Ku SY, Venkadakrishnan VB, Korsen JA, Kalidindi TM, Mizuno K, Ahn SH, Seo JH, Garcia MM, Khani F, Elemento O, Long HW, Chaglassian A, Pillarsetty N, Lewis JS, Freedman M, Belanger AP, Nguyen QD, Beltran H. Bakht MK, et al. Among authors: yamada y. Nat Cancer. 2023 May;4(5):699-715. doi: 10.1038/s43018-023-00539-6. Epub 2023 Apr 10. Nat Cancer. 2023. PMID: 37038004 Free PMC article.
L-type amino acid transporter 1 inhibitor JPH203 prevents the growth of cabazitaxel-resistant prostate cancer by inhibiting cyclin-dependent kinase activity.
Rii J, Sakamoto S, Mizokami A, Xu M, Fujimoto A, Saito S, Koike H, Tamura T, Arai T, Yamada Y, Goto Y, Sazuka T, Imamura Y, Suzuki K, Kanai Y, Anzai N, Ichikawa T. Rii J, et al. Among authors: yamada y. Cancer Sci. 2024 Mar;115(3):937-953. doi: 10.1111/cas.16062. Epub 2024 Jan 7. Cancer Sci. 2024. PMID: 38186218 Free PMC article.
Functional analysis of LAT3 in prostate cancer: Its downstream target and relationship with androgen receptor.
Rii J, Sakamoto S, Sugiura M, Kanesaka M, Fujimoto A, Yamada Y, Maimaiti M, Ando K, Wakai K, Xu M, Imamura Y, Shindo N, Hirota T, Kaneda A, Kanai Y, Ikehara Y, Anzai N, Ichikawa T. Rii J, et al. Among authors: yamada y. Cancer Sci. 2021 Sep;112(9):3871-3883. doi: 10.1111/cas.14991. Epub 2021 Jul 8. Cancer Sci. 2021. PMID: 34050700 Free PMC article.
Impact of Portal Flow on the Prognosis of Children With Congenital Portosystemic Shunt: A Multicentric Observation Study in Japan.
Uchida H, Shinkai M, Okuyama H, Ueno T, Inoue M, Yasui T, Hiyama E, Kurihara S, Sakuma Y, Sanada Y, Taketomi A, Honda S, Wada M, Ando R, Fujishiro J, Yoshida M, Yamada Y, Uchida H, Tainaka T, Kasahara M; Japanese Society of Pediatric Splenology and Portalvenology. Uchida H, et al. Among authors: yamada y. J Pediatr Surg. 2024 May 17:S0022-3468(24)00309-9. doi: 10.1016/j.jpedsurg.2024.05.008. Online ahead of print. J Pediatr Surg. 2024. PMID: 38839469
Proteomic analysis of serum extracellular vesicles reveals Fibulin-3 as a new marker predicting liver-related events in MASLD.
Sakane S, Hikita H, Shirai K, Sakamoto T, Narumi R, Adachi J, Kakita N, Yamada Y, Toyoda H, Takahashi H, Suda G, Kai M, Tahata Y, Sakamori R, Kumazaki S, Fukumoto K, Myojin Y, Murai K, Kodama T, Tatsumi T, Tomonaga T, Sakamoto N, Morii E, Takehara T. Sakane S, et al. Among authors: yamada y. Hepatol Commun. 2024 Jun 3;8(6):e0448. doi: 10.1097/HC9.0000000000000448. eCollection 2024 Jun 1. Hepatol Commun. 2024. PMID: 38829196 Free PMC article.
Risk factors for severe immune-related pneumonitis after nivolumab plus ipilimumab therapy for non-small cell lung cancer.
Sumi T, Sekikawa M, Koshino Y, Nagayama D, Nagahisa Y, Matsuura K, Shijubou N, Kamada K, Suzuki K, Ikeda T, Michimata H, Watanabe H, Yamada Y, Osuda K, Tanaka Y, Chiba H. Sumi T, et al. Among authors: yamada y. Thorac Cancer. 2024 Jun 3. doi: 10.1111/1759-7714.15385. Online ahead of print. Thorac Cancer. 2024. PMID: 38828610 Free article.
9,736 results